DNLI

Denali Therapeutics (DNLI)

About Denali Therapeutics (DNLI)

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Details

Daily high

$17.30

Daily low

$16.81

Price at open

$16.88

52 Week High

$24.34

52 Week Low

$10.57

Market cap

2.6B

Dividend yield

0.00%

Volume

2.1M

Avg. volume

1.9M

P/E ratio

-5.79

Denali Therapeutics News